Stay updated on Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now shows Revision: v3.3.2 in the footer, replacing the previous Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedThe banner about a lapse in government funding has been removed from the page. This notice did not affect the study details or participation requirements.SummaryDifference0.4%

- Check42 days agoChange DetectedResults have been posted (Results First Posted 2025-07-20) with updated primary and secondary outcomes and safety data.SummaryDifference0.5%

- Check71 days agoChange DetectedSignificant update: new operating-status notice and version bump to v3.2.0; previous v3.1.0 tag removed. Core content impacted by the new status information.SummaryDifference3%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0, indicating a newer release.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2. The Back to Top link was removed; no other substantive changes were detected.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.